World Health Authority. Gonorrhoea (Neisseria gonorrhoeae infection) fact sheet. 2024. https://www.who.int/. Accessed 4 Jun 2025.

He Y, Zhao J, Wang L, et al. Epidemiological trends and predictions of urinary tract infections in the global burden of disease study 2021. Sci Rep. 2025;15(1):4702.

CAS  PubMed  PubMed Central  Google Scholar 

Watkins RR, Thapaliya D, Lemonovich TL, et al. Gepotidacin: a novel, oral, “first-in-class” triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea. J Antimicrob Chemother. 2023;78(5):1137–42.

CAS  PubMed  Google Scholar 

Perry C, Hossain M, Powell M, et al. Design of two phase 3, randomized, multicenter studies comparing gepotidacin with nitrofurantoin for the treatment of uncomplicated urinary tract infection in female participants. Infect Dis Ther. 2022;11(6):2297–310.

PubMed  PubMed Central  Google Scholar 

Ali ASM, Anderson CS. Gepotidacin, a new first-in-class antibiotic for treating uncomplicated urinary tract infection. Lancet. 2024;403(10428):702–3.

CAS  PubMed  Google Scholar 

Golparian D, Cole MJ, Sánchez-Busó L, et al. Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study. Lancet Microbe. 2024;5(5):e478–88.

PubMed  Google Scholar 

GSK. Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older [media release]. 25 Mar 2025. https://www.gsk.com/.

GSK. Gepotidacin: US prescribing information. 2025. https://blujepa.com/. Accessed 26 Mar 2025

GSK. 2025 first quarter: GSK makes strong start to 2025 with growth in sales, profits and earnings [media release]. 30 Apr 2025. https://www.gsk.com/.

O’Riordan W, Tiffany C, Scangarella-Oman N, et al. Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed Gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61(6):1–12.

Google Scholar 

Oviatt AA, Gibson EG, Huang J, et al. Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: genetic and biochemical evidence for well-balanced dual-targeting. ACS Infect Dis. 2024;10(4):1137–51.

CAS  PubMed  PubMed Central  Google Scholar 

Biedenbach DJ, Bouchillon SK, Hackel M, et al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother. 2016;60(3):1918–23.

CAS  PubMed  PubMed Central  Google Scholar 

Arends SJR, Butler D, Scangarella-Oman N, et al. Antimicrobial activity of gepotidacin tested against Escherichia coli and Staphylococcus saprophyticus isolates causing urinary tract infections in medical centers worldwide (2019 to 2020). Antimicrob Agents Chemother. 2023;67(4):1–9.

CAS  Google Scholar 

Kresken M, Wohlfarth E, Weikel C, et al. In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany. J Antimicrob Chemother. 2022;78(2):418–22.

Google Scholar 

Arends SJR, Kapoor R, Torumkuney D. Analysis of resistance to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Staphylococcus saprophyticus collected in the United States in 2022 [abstract no. 2159]. Open Forum Infect Dis. 2023;10(Suppl 2):S911–2.

Google Scholar 

Arends S, Kapoor R, Torumkuney D. In vitro activity of gepotidacin and comparator agents against a collection of K. pneumoniae urine isolates collected from Europe during 2019–2022 [abstract no P2433 | 02048]. CMI Commun. 2024;1(1 Suppl):2691.

Google Scholar 

Mendes R, Arends S, Kimbrough J, et al. Activity of gepotidacin against molecularly characterised Klebsiella pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2019-2022) [abstract no. P2479 | 04707]. CMI Commun. 2024;1(1 Suppl):2740–1.

Google Scholar 

Jacobsson S, Golparian D, Scangarella-Oman N, et al. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. J Antimicrob Chemother. 2018;73(8):2072–7.

CAS  PubMed  PubMed Central  Google Scholar 

Scangarella-Oman NE, Hossain M, Dixon PB, et al. Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2018;62(12):1–10.

Google Scholar 

Farrell DJ, Sader HS, Rhomberg PR, et al. In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017;61(3):1–7.

Google Scholar 

Bulik CC, Okusanya ÓO, Lakota EA, et al. Pharmacokinetic-pharmacodynamic evaluation of gepotidacin against Gram-positive organisms using data from murine infection models. Antimicrob Agents Chemother. 2017;61(2):1–12.

Google Scholar 

VanScoy BD, Scangarella-Oman NE, Fikes S, et al. Relationship between gepotidacin exposure and prevention of on-therapy resistance amplification in a Neisseria gonorrhoeae hollow-fiber in vitro infection model. Antimicrob Agents Chemother. 2020;64(10):1–9.

Google Scholar 

VanScoy BD, Lakota EA, Conde H, et al. Gepotidacin pharmacokinetics-pharmacodynamics against Escherichia coli in the one-compartment and hollow-fiber in vitro infection model systems. Antimicrob Agents Chemother. 2021;65(12):1–10.

Google Scholar 

Hossain M, Zhou M, Tiffany C, et al. A phase 1, randomized, double-blinded, placebo- and moxifloxacin-controlled, four-period crossover study to evaluate the effect of gepotidacin on cardiac conduction as assessed by 12-lead electrocardiogram in healthy volunteers. Antimicrob Agents Chemother. 2017;61(5):588–97.

Google Scholar 

US Food and Drug Administration. Blujepa (gepotidacin) integrated review. 2025. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed 4 Jul 2025.

Wagenlehner F, Perry CR, Hooton TM, et al. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet. 2024;403(10428):741–55.

CAS  PubMed  Google Scholar 

Overcash JS, Tiffany CA, Scangarella-Oman NE, et al. Phase 2a pharmacokinetic, safety, and exploratory efficacy evaluation of oral gepotidacin (GSK2140944) in female participants with uncomplicated urinary tract infection (acute uncomplicated cystitis). Antimicrob Agents Chemother. 2020;64(7):1–13.

Google Scholar 

Ross JDC, Wilson J, Workowski KA, et al. Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. Lancet. 2025;405(10489):1608–20.

CAS  PubMed  Google Scholar 

Taylor SN, Morris DH, Avery AK, et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis. 2018;67(4):504–12.

CAS  PubMed  PubMed Central  Google Scholar